Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRUCE trial of zodasiran in adolescents with homozygous familial hypercholesterolemia
NL-OMON61384Phase 3Not yet recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jul 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of zodasiran in homozygous familial hypercholesterolemia (HoFH), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Percent change from baseline to Month 12 in fasting LDL-C. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
zodasiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NL-OMON61384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61384.